Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Bought 50,000 shares at weighted avg $18.32 on June 30 (ranging $18.29–$18.32), one day before the company's $100M public offering closed at $20/share. True open-market purchase below offering price. Serial accumulator: 25 buys, 0 sells over 5 years. Now $19.52 (+6.5% since buy).
Bought 12,500 shares at $20.00/share on June 30 — exactly the public offering price announced June 29. Likely directed-share participation in the $100M offering, not pure open-market. CEO commitment buy alongside the deal. Now $19.52 (−2.4% since buy). Post-transaction holdings: 3,688,424 shares.
AIThe day in insider buying
SEC Form 4 Insider Scan — July 2, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (filed July 1–2, 2026). 2 qualifying buys (≥ $250K, transaction type P) totalling $1.17M.
Data note: Direct EDGAR / aggregator endpoints (sec.gov, efts.sec.gov, openinsider.com, finviz.com) are blocked by the session egress policy. Data sourced from web-search snippets via Quiver Quantitative, StockTitan, Investing.com, and Globe Newswire; NVCT spot from Tradier fetch_quote.
Headline filings
NVCT — Marlio Charles Mosseri (10% Owner) bought 50,000 shares ≈ $916K at $18.32 avg (June 30, filed July 1); now $19.52 (+6.5% since buy). Mosseri is a serial NVCT accumulator — 25 buys, 0 sells over 5 years. Purchased on the open market one day ahead of the company's $100M public offering closing at $20, signalling conviction at a discount to the deal price. (EDGAR filings)
NVCT — Ron Bentsur (Chairman & CEO) bought 12,500 shares ≈ $250K at $20.00 (June 30, filed July 1); now $19.52 (−2.4% since buy). Purchase price matches the offering price exactly — likely a directed-share participation in the same $100M offering announced June 29. CEO skin-in-the-game alongside the deal. (EDGAR filings)
Notes
Single-stock cluster: Both qualifying buys are in Nuvectis Pharma (NVCT), a ~$160M-market-cap oncology biotech. The company priced a $100M public offering on June 29 at $20/share (closing July 1). A 10% owner buying 50K shares below the offering price on the open market the day before closing is the more meaningful signal — Mosseri appears to be adding ahead of expected catalysts. The CEO's co-purchase at the offering price rounds out insider commitment.
Other July 1 P-coded filings scanned but below the $250K threshold: Polestar (PSNY) director 6,000 ADSs (~$102K), Hyperscale Data (GPUS) CEO 5,000 preferred shares (~$95K), Simon Property Group (SPG) directors 508–508 shares each (~$114K per transaction), Casey's General Stores (CASY) director 256 shares (~$199K), SWZ director 4,091 shares (~$24K).
Biotech / small-cap focus: The $250K+ bar filtered most routine accumulator purchases at larger-cap names. No large-cap CEO discretionary buys identified in this 24-hour window.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.